Wedbush Predicts Weaker Earnings for Fennec Pharmaceuticals

Key Points

• Wedbush has downgraded its earnings per share estimate for Fennec Pharmaceuticals for FY2025 from $0.59 to $0.44, while the consensus estimate remains at $0.60.
• Fennec Pharmaceuticals' shares increased 4.2% on Monday, trading at C$11.84, with a market cap of C$228.33 million.
• Insider transactions included the sale of 10,000 shares by Director Rostislav Christov Raykov and a purchase of 8,220 shares by Senior Officer Robert Christopher Andrade.

Fennec Pharmaceuticals Inc. (TSE:FRX - Free Report) - Investment analysts at Wedbush reduced their FY2025 earnings estimates for Fennec Pharmaceuticals in a research report issued to clients and investors on Thursday, August 14th. Wedbush analyst D. Nierengarten now expects that the biopharmaceutical company will post earnings per share of $0.44 for the year, down from their prior estimate of $0.59. The consensus estimate for Fennec Pharmaceuticals' current full-year earnings is $0.60 per share. Wedbush also issued estimates for Fennec Pharmaceuticals' Q4 2025 earnings at $0.10 EPS.

Fennec Pharmaceuticals Stock Performance

Shares of FRX traded up C$0.49 on Monday, reaching C$11.94. The company's stock had a trading volume of 406 shares, compared to its average volume of 1,048. The company has a debt-to-equity ratio of -620.83, a current ratio of 7.80 and a quick ratio of 10.17. The stock has a market capitalization of C$230.26 million, a P/E ratio of -202.26 and a beta of 0.25. The stock's 50 day simple moving average is C$11.54 and its two-hundred day simple moving average is C$10.00. Fennec Pharmaceuticals has a 12-month low of C$5.65 and a 12-month high of C$12.99.

Insider Activity at Fennec Pharmaceuticals

In other news, Senior Officer Robert Christopher Andrade bought 8,220 shares of Fennec Pharmaceuticals stock in a transaction that occurred on Monday, June 2nd. The stock was bought at an average cost of C$6.99 per share, with a total value of C$57,433.14. Also, Director Rostislav Christov Raykov sold 10,000 shares of the stock in a transaction that occurred on Thursday, July 3rd. The stock was sold at an average price of C$11.71, for a total transaction of C$117,096.00. Insiders sold a total of 23,246 shares of company stock valued at $243,883 over the last three months. 16.20% of the stock is currently owned by insiders.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc is a clinical-stage biotechnology company. It is primarily engaged in research and development activities. The company is developing Sodium Thiosulfate (STS), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. Its lead product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin induced hearing loss, or ototoxicity in children.